Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
bbp-812 save search
BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments
Published: 2023-10-03 (Crawled : 12:00) - bridgebio.com
BBIO | $25.07 1.33% 1.39% 1.9M
|
Health Technology
|
| O: 0.0%
H: 1.4%
C: 0.08%
bbp-631 partnership multi-year bbp-812 therapy
BridgeBio Pharma Presents Updated Encouraging Clinical and Biomarker Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Published: 2023-05-22 (Crawled : 12:00) - globenewswire.com
BBIO | $25.07 1.33% 1.39% 1.9M
|
Health Technology
|
| O: 0.73%
H: 1.66%
C: -0.8%
bbp-812 pharma disease biomarker cell meeting program therapy
BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Published: 2023-05-15 (Crawled : 12:00) - globenewswire.com
BBIO | $25.07 1.33% 1.39% 1.9M
|
Health Technology
|
| O: 0.41%
H: 10.0%
C: 9.12%
bbp-812 pharma disease cell meeting program therapy
BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)
Published: 2022-10-14 (Crawled : 15:20) - biospace.com/
BBIO | $25.07 1.33% 1.39% 1.9M
|
Health Technology
|
| O: 3.77%
H: 0.45%
C: -10.34%
bbp-418 pharma results study phase 2
BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease
Published: 2022-06-22 (Crawled : 12:00) - biospace.com/
BBIO | $25.07 1.33% 1.39% 1.9M
|
Health Technology
|
| O: -1.02%
H: 12.96%
C: 8.61%
bbp-812 pharma disease aav9 positive therapy
BridgeBio Pharma Affiliate Venthera Presents Preliminary Results from Clinical Trial of VT30 (BBP-681) for Venous, Lymphatic, and Venolymphatic Malformations
Published: 2022-06-10 (Crawled : 12:00) - globenewswire.com
BBIO | $25.07 1.33% 1.39% 1.9M
|
Health Technology
|
| O: -3.07%
H: 0.0%
C: 0.0%
vt30 pharma trial
BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)
Published: 2021-02-19 (Crawled : 13:00) - globenewswire.com
BBIO | $25.07 1.33% 1.39% 1.9M
|
Health Technology
|
| O: 3.37%
H: 4.94%
C: 1.03%
phase 2 trial
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
VIVK | $1.43 33.65% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
SDIG A | $3.64 35.32% 26.0% 990K
|
PROK | $2.72 33.33% 24.58% 2.6M
|
Your saved searches
Save your searches and get alerts when important news are released.